...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current medical research and opinion >Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers
【24h】

Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers

机译：在一组芬兰成年吸烟者中，伐尼克兰，安非他酮和无辅助戒烟的成本效益

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To assess the cost effectiveness of varenicline compared with bupropion or unaided cessation for smoking cessation in Finnish adult smokers. The BENESCO (BENEfits of Smoking Cessation on Outcomes) Markov model was used to follow a hypothetical cohort of smokers making a single quit attempt over a lifetime. Gender and age-specific data on the incidence and prevalence of five smoking-related diseases (chronic obstructive pulmonary disease [COPD], lung cancer, coronary heart disease [CHD], stroke and asthma exacerbations) were included in the model. Life-years (LYs), quality-adjusted life-years (QALYs), total treatment costs and the lifetime cumulative incidence of these parameters were the primary outcomes evaluated, and they were compared for varenicline versus bupropion and varenicline versus unaided cessation. The primary data were derived from Finnish publications and databases. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the base-case model. The treatment cohort comprised 229 301 smokers making a quit attempt. In the lifetime simulation, use of varenicline prevented 1965 and 5057 additional cases of smoking-related disease, and 1184 and 3047 deaths attributable to smoking, when compared with bupropion and unaided cessation, respectively. Compared with bupropion and unaided cessation varenicline treatment yielded 4392 and 11 303 additional LYs (4851 and 12 485 QALYs), respectively. Varenicline resulted in cost savings of 15 million and 43 million euros (?) compared with bupropion and unaided cessation, respectively. In the 20-year time horizon analysis, varenicline yielded an incremental cost-effectiveness ratio (ICER) of ?8791/QALY and ?7791/QALY gained in comparison to bupropion and unaided cessation, respectively. Sensitivity analyses supported the robustness of the base-case results for varenicline. Varenicline dominated over its comparators, i.e. it was more effective and resulted in cost saving compared with bupropion and unaided cessation.
机译：在芬兰成年吸烟者中评估伐尼克兰与安非他酮或无辅助戒烟相比的成本效益。 BENESCO（因结果而戒烟的收益）马尔可夫模型用于追踪假设的吸烟者群体，在一生中仅进行一次戒烟尝试。该模型包括五种吸烟相关疾病（慢性阻塞性肺疾病[COPD]，肺癌，冠心病[CHD]，中风和哮喘加重）的发病率和流行率的性别和年龄特定数据。生命年（LYs），质量调整生命年（QALYs），总治疗费用和这些参数的终生累积发生率是评估的主要结局，并比较了伐尼克兰与安非他酮，伐尼克兰与无辅助戒烟的情况。主要数据来自芬兰出版物和数据库。进行了确定性和概率敏感性分析，以测试基本案例模型的鲁棒性。该治疗队列包括229 301名戒烟者。在终生模拟中，与安非他酮和无辅助戒烟相比，使用缬尼克林可分别预防1965和5057例与吸烟有关的疾病，以及1184和3047例与吸烟有关的死亡。与安非他酮和无辅助戒断相比，伐尼克兰治疗分别产生4392和11 303 LYs（4851和12 485 QALYs）。与安非他酮和无辅助戒烟相比，Varenicline分别节省了1500万欧元和4300万欧元（？）。在20年的时间跨度分析中，与安非他酮和无辅助戒断相比，缬尼克林产生的成本效益比（ICER）分别为8791 / QALY和7791 / QALY。敏感性分析支持了法尼尼克林基本案例结果的稳健性。瓦伦尼克碱在其比较剂中占主导地位，即与安非他酮和无辅助戒烟相比，它更有效并节省了成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号